Humacyte, Inc. (HUMA), a clinical-stage biotechnology platform company, on Friday announced a registered direct offering of around $30 million worth of its shares and warrants.
The gross proceeds from the offering are expected to be around $30 million.
The company has agreed to sell 5.681 million shares of its shares and warrants to purchase 5.681 million shares. The offering will be closed on or about October 7.
As many as 2.840 million warrants will be exercisable immediately, with an exercise price of $5.28 per share. The purchase price of one share and one warrant will be $5.28.
HUMA was trading up by 5.84 percent at $5.59 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.